ARISTADA

Serial Number 87189103
Registration 5392594
702

Registration Progress

Application Filed
Sep 30, 2016
Under Examination
Aug 22, 2017
Approved for Publication
Feb 28, 2017
Published for Opposition
Feb 28, 2017
Registered
Jan 30, 2018

Trademark Image

ARISTADA

Basic Information

Serial Number
87189103
Registration Number
5392594
Filing Date
September 30, 2016
Registration Date
January 30, 2018
Published for Opposition
February 28, 2017
Drawing Code
3

Status Summary

Current Status
Active
Status Code
702
Status Date
Jun 14, 2024
Registration
Registered
Classes
005

Rights Holder

Alkermes Pharma Ireland Limited

03
Address
1 Burlington Road, Connaught House
Dublin
IE

Ownership History

Alkermes Pharma Ireland Limited

Original Applicant
03
Dublin IE

Alkermes Pharma Ireland Limited

Owner at Publication
03
Dublin IE

Alkermes Pharma Ireland Limited

Original Registrant
03
Dublin IE

Legal Representation

Attorney
Norm J. Rich

USPTO Deadlines

Next Deadline
924 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2018-01-30)
Due Date
January 30, 2028
Grace Period Ends
July 30, 2028

Application History

40 events
Date Code Type Description Documents
Jun 14, 2024 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED Loading...
Jun 14, 2024 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. Loading...
Jun 14, 2024 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Dec 11, 2023 E815 I TEAS SECTION 8 & 15 RECEIVED Loading...
Jan 30, 2023 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Jan 30, 2018 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Dec 29, 2017 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Dec 28, 2017 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Dec 28, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 28, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 26, 2017 ALIE A ASSIGNED TO LIE Loading...
Dec 15, 2017 ALIE A ASSIGNED TO LIE Loading...
Dec 7, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Nov 28, 2017 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Nov 28, 2017 ZZAX Z PREVIOUS ALLOWANCE WITHDRAWN-TIMELY AAU Loading...
Nov 28, 2017 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Nov 28, 2017 GNRT O NON-FINAL ACTION E-MAILED Loading...
Oct 3, 2017 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Oct 2, 2017 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Sep 23, 2017 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Sep 22, 2017 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Sep 11, 2017 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Sep 11, 2017 IUAF S USE AMENDMENT FILED Loading...
Aug 22, 2017 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jul 9, 2017 ETOP T EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED Loading...
Mar 29, 2017 ETOF T EXTENSION OF TIME TO OPPOSE RECEIVED Loading...
Feb 28, 2017 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 28, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 8, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 22, 2017 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 20, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 19, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 19, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jan 17, 2017 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jan 17, 2017 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jan 17, 2017 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jan 10, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 6, 2016 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Oct 5, 2016 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 4, 2016 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases; Pharmaceutical compounds, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases, cardiovascular diseases and metabolic diseases
First Use Anywhere: Jun 27, 2017
First Use in Commerce: Jun 27, 2017

Additional Information

Design Mark
The mark consists of the stylized dark red wording "ARISTADA". To the right is a design comprised of a gray diamond shape. One set of double bands of varying length and width runs horizontally to each of the diamond's four sides. Each double band set is a single color - light blue, dark blue, dark red and green. All of the foregoing elements are separated by a white space, with the mark appearing on a white background.
Color Claim
The color(s) red, dark blue, light blue, green, gray and white is/are claimed as a feature of the mark.

Classification

International Classes
005